Subscribe To
ENTA / Open Orphan client sees positive results in human challenge study
ENTA News
By Business Wire
September 17, 2023
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, sma more_horizontal
By Seeking Alpha
August 7, 2023
Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor R more_horizontal
By Zacks Investment Research
August 7, 2023
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares more_horizontal
By Market Watch
June 20, 2023
Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial
Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-ph more_horizontal
By Zacks Investment Research
May 8, 2023
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares more_horizontal
By Business Wire
March 8, 2023
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Rese
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. more_horizontal
By Business Wire
March 8, 2023
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Rese
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. more_horizontal
By Business Wire
March 7, 2023
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small mole more_horizontal